Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common and complex inflammatory disorder in the upper airway. Type 2 inflammation affects the severity of CRSwNP and recurrence of polyps, determining the pharmacotherapy and extent of surgery, also associated with asthma comorbidity.
1 Over the past decade, biologics targeting the biomarkers of type 2 immune reaction ---- IL-4, IL-5, and IgE, have been applied to CRSwNP in phase 2 or 3 clinical trials and emerged as an effective treatment option.
However, until now, the safety of these biologics has not been systematically analyzed. Thus, this study aimed to observe the incidence of adverse events (AEs) following the use of biologics, to estimate the safety of biologics in CRSwNP.
A systematic search of PubMed, Medline, and Web of Science from January 2005 to May 2021 using the search terms “monoclonal antibody”, “dupilumab”, “mepolizumab” and “omalizumab” and ‘‘nasal polyposis’’ was conducted...
Read more
PDF
No comments:
Post a Comment